Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Prima BioMed Ltd (NASDAQ:PBMD)

1.18
Delayed Data
As of Aug 03
 +0.03 / +2.61%
Today’s Change
0.42
Today|||52-Week Range
6.48
+76.09%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$52.7M

Company Description

Prima BioMed Ltd. is a biotechnology company, which has focused on developing novel oncology therapies in the field of immunotherapy. The company's core product is CVac, which is vaccine therapy treatment for ovarian cancer patients administered post-surgery and post-chemotherapy to delay the relapse of and control the metastases of the cancer. It operates through two segments, including Cancer Immunotherapy and Other R & D. Prima BioMed as founded on May 21, 1987 and is headquartered in Sydney, Australia.

Contact Information

Prima BioMed Ltd.
151 Macquarie Street
Sydney New South Wales (nsw) 2000
P:(129) 276-1224
Investor Relations:

Employees

Shareholders

Mutual fund holders--
Individual stakeholders--
Other institutional--

Top Executives

Marc VoigtChief Executive Officer & Executive Director
Sharron E. GargoskyChief Technology Officer
Frédéric TriebelChief Scientific & Medical Officer
Larisa ChisholmManager-Business Development
Stuart RobertsGlobal Head-Investor Relations